化合物 AZD4547|T1948|TargetMol

2篇文獻(xiàn)

價(jià)格	￥263	￥371	￥617
包裝	1mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 AZD4547	英文名稱:AZD4547
CAS:1035270-39-3	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.83%	產(chǎn)品類別: 抑制劑
貨號(hào): T1948

Product Introduction

Bioactivity

名稱	AZD4547
描述	AZD4547 is an FGFR family inhibitor. AZD4547 selectively inhibits FGFR1 phosphorylation and suppresses cancer cell proliferation through inhibition of FGFR1 signaling, and is able to act on FGFR1 (IC50:0.2 nM), FGFR2 (IC50:2.5 nM), FGFR3 (IC50:1.8 nM) and FGFR4 (IC50:165 nM). IC50:165 nM).[2]
細(xì)胞實(shí)驗(yàn)	Cell lines were incubated with fixed concentrations of AZD4547 for 72 hours. For fluorescence-activated cell sorting (FACS), cells were fixed with 70% ethanol and then incubated with propidium iodide/RNase A labeling solution. Cell-cycle profiles were assessed with a FACSCalibur instrument and CellQuest analysis software. For apoptotic analysis, cells and media were gently harvested and centrifuged, followed by washing of cell pellets. Cells were then processed for Annexin V-fluorescein isothiocyanate (FITC) staining and propidium iodide uptake according to the manufacturer's instructions. The proportion of cells staining positive for Annexin V were then assessed with a FACSCalibur instrument and quadrant sorting was done by CellQuest analysis software [1].
激酶實(shí)驗(yàn)	Cells were treated with AZD4547 or control for 3 hours at 37°C and then stimulated with 10 ng/mL aFGF/bFGF and 10 μg/mL heparin for 20 minutes. Western blotting was conducted with standard SDS-PAGE procedures and antibody incubation carried out overnight at 4°C. Secondary antibodies were applied and immunoreactive proteins visualized with Chemiluminescence substrate according to the manufacturer's instructions [1].
動(dòng)物實(shí)驗(yàn)	Tumor xenografts were established by s.c. injection into the left flank with 0.1 mL tumor cells (1 × 10^6 for LoVo, 1 × 10^7 for HCT-15, and 1 × 10^7 for Calu-6) or 0.2 mL (2 × 10^7 for KMS11 and KG1a) mixed 1:1 with Matrigel, with the exception of LoVo and HCT-15, which did not include Matrigel. Mice were randomized into control and treatment groups when tumors reached the determined size of more than 0.2 cm3. Tumor volume (measured by caliper), animal body weight, and tumor condition were recorded twice weekly for the duration of the study. Tumor volume was calculated as described previously [1].
體外活性	方法：NRK-52E細(xì)胞用2.5,5,10,20μM AZD4547預(yù)處理1小時(shí)，然后暴露于0.5μg/ mLLPS指定時(shí)間，觀察AZD4547對(duì)NRK-52E細(xì)胞中 LPS 誘導(dǎo)的炎癥缺陷。結(jié)果：AZD4547在NRK-52E細(xì)胞中以20μM的濃度顯著抑制細(xì)胞增殖。[2] 方法：NRK-52E細(xì)胞用10μM AZD4547預(yù)處理1小時(shí)，然后暴露于0.5μg/ mL LPS指定時(shí)間，研究了 NRK-52E 細(xì)胞中促炎因子的水平。結(jié)果：AZD4547通過減少NRK-52E細(xì)胞中的TAK1/NF-κB信號(hào)通路來減弱LPS誘導(dǎo)的炎癥因子。[2]
體內(nèi)活性	方法：C57BL/6 小鼠使用LPS（15 mg/kg，腹膜內(nèi)注射）并用AZD4547治療（在LPS治療前1小時(shí)灌胃40 mg/kg），研究 AZD4547 在 LPS 誘導(dǎo)的急性腎損傷中的腎保護(hù)作用以及測(cè)量了促凋亡基因Bax和抗凋亡基因Bcl-2研究AZD4547對(duì)AKI中保留腎功能的影響是否通過調(diào)節(jié)細(xì)胞凋亡來介導(dǎo)。結(jié)果：AZD4547可以預(yù)防LPS相關(guān)的腎功能不全，細(xì)胞凋亡和小鼠腎臟炎癥。[1]
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 50 mg/mL (107.86 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble)
關(guān)鍵字	Inhibitor \| Fibroblast growth factor receptor \| FGFR \| AZD 4547 \| inhibit \| AZD-4547 \| AZD4547
相關(guān)產(chǎn)品	Amlexanox \| Ribociclib \| Formononetin \| Axitinib \| Sorafenib tosylate \| Lenvatinib mesylate \| Ferulic Acid \| Regorafenib \| Pazopanib \| Nintedanib \| Sorafenib \| Regorafenib monohydrate
相關(guān)庫	抑制劑庫 \| 經(jīng)典已知活性庫 \| 抗癌活性化合物庫 \| 已知活性化合物庫 \| 激酶抑制劑庫 \| 膜蛋白靶向化合物庫 \| 酪氨酸激酶分子庫 \| 藥物功能重定位化合物庫 \| 抗癌臨床化合物庫 \| 抗癌藥物庫

關(guān)鍵字： AZD4547|TargetMol

公司簡(jiǎn)介

上海陶術(shù)生物科技有限公司為美國(guó)Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國(guó)波士頓、德國(guó)慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實(shí)體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個(gè)性化定制合成；從對(duì)明確靶點(diǎn)的分子篩選到對(duì)明確分子的多靶點(diǎn)篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過在中國(guó)市場(chǎng)五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.2651萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營(yíng)模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊(cè)資本：566.2651萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑，藥物篩選化合物庫，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場(chǎng)三路28號(hào)4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

多樣性化合物庫

￥5000

篩選化合物庫

￥100000

化合物 CI994|T1888

￥198